
Stress disorders often stem from imbalances in the brain’s neurotransmitter systems, which can disrupt emotional regulation and cognitive function. Utilizing our deep expertise in ion channel biology, medicinal chemistry, formulation development and translational sciences, we design best-in-class oral, small molecules to modulate neurotransmission and downstream signaling in the brain.


7% of people in the U.S. will experience PTSD in their lifetime. Despite this, current treatments come with significant drawbacks, including sedation, cognitive impairment, and addiction risks. The need for better solutions has never been clearer.
BNC210 works as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR). This differentiated mechanism has shown promise in multiple studies for treating PTSD, and related neuropsychiatric disorders—offering hope for rapid and long-lasting, broad-spectrum anxiety and stress relief.

BNC210 is currently ready for late-stage trials for PTSD, with potential applications in generalized anxiety disorder (GAD), panic attacks, and beyond.
Discover how our groundbreaking technology is transforming mental health—contact us today to learn more.